The therapeutic profile of olmesartan medoxomil, which is a recently developed angiotensin II (A II) 
Introduction
An angiotensin II (A II) receptor blocker is often reserved as an alternative for patients who develop cough as a side-effect when given angiotensinconverting enzyme (ACE) inhibitor therapy. Views, however, are changing and A II receptor blockers are becoming increasingly accepted as first-line treatment options for essential hypertension. The change in prescribing habits for A II receptor blockers has been prompted not only by their proven efficacy and good tolerability, 1 but also by data indicating organprotective effects. There is clinical evidence suggesting that A II receptor blockers may confer cardioprotective effects superior to those conferred by other classes of antihypertensives, while achieving similar decreases in blood pressure (BP). 2 A more persistent improvement in renal haemodynamics has also been demonstrated for A II receptor blockers in comparison with ACE inhibitors, despite equivalent BP reduction. 3 This could be important in cases of dia- betic nephropathy and chronic renal failure. Furthermore, expert opinion suggests that, before they prescribe longer-established antihypertensives, clinicians should consider all data concerning organ-protective effects conferred by A II receptor blockers. [4] [5] [6] Olmesartan medoxomil is a recently developed A II receptor blocker. Olmesartan medoxomil is neither a substrate for, nor an inhibitor or inducer of, cytochrome P-450 isoforms. 7, 8 This property, along with other general pharmacokinetic properties, limits the risk of pharmacokinetic interactions between olmesartan once daily (o.d.) and other co-administered drugs. 7, 8 The therapeutic profile of olmesartan has been compared with those of four commonly used antihypertensives during the pre-launch clinical development phase of this novel A II receptor blocker. One study compared the efficacy of olmesartan with that of the ␤-adrenoceptor blocker atenolol (plus hydrochlorothiazide (HCTZ) background therapy) in patients with moderate-to-severe hypertension. A further four studies of patients with mild-to-moderate hypertension were carried out to compare the efficacy of olmesartan with that of atenolol, the ACE inhibitor captopril, the calcium antagonist felodipine, and the A II receptor blocker losartan, respectively. These five multicentre, randomized, doubleblind, parallel-group, phase III trials were designed to compare individually optimized dosages of olmesartan and the comparator agent. The primary efficacy variable in all trials was the mean change from baseline to week 12 in trough (pre-dose) mean sitting diastolic BP (DBP). Patients were recruited from primary-care centres in Germany, Poland, Czech Republic, France, Belgium, The Netherlands, the UK and the Republic of Ireland. Existing antihypertensive therapy was discontinued before entry into the study, and hypertension severity was confirmed by the mean of three sitting DBP measurements taken on two or three separate occasions during the runin period. Details of the trials comparing olmesartan with atenolol (moderate-to-severe hypertension), captopril and losartan have been reported previously. 9 The major results for all five trials are presented in order to provide prescribers with a comprehensive assessment of the efficacy of olmesartan compared with commonly used antihypertensives.
Comparison with atenolol in patients with moderate-to-severe hypertension
The efficacy of olmesartan was compared with that of atenolol in patients with moderate-to-severe hypertension. Moderate-to-severe hypertension was defined as a mean sitting DBP of 100-120 mm Hg. 
Comparison with atenolol in patients with mild-to-moderate hypertension
In another study, olmesartan was compared with atenolol in patients with mild-to-moderate hypertension, defined as a mean sitting DBP of 95-114 mm Hg after a 3-week placebo run-in phase. A total of 165 patients (baseline mean DBP of 100.8 mm Hg) were randomized to receive olmesartan medoxomil 10 mg o.d., and a further 161 patients (baseline mean DBP of 101.0 mm Hg) received atenolol 50 mg o.d. At week 4, the dose was doubled for non-responders in each group.
In terms of the primary efficacy variable, the mean changes from baseline to week 12 in DBP were comparable for both treatment regimens (Figure 1) . A significant difference between the groups was seen in the mean changes from baseline in SBP, however, with a greater decrease at 12 weeks in olmesartantreated patients compared with atenolol-treated patients. Table 1 shows that some superiority of olmesartan compared with atenolol, in terms of a decrease in SBP, was already evident after 4 and 8 weeks of treatment.
The responder rate at week 12 was 78% for patients receiving olmesartan medoxomil and 79% for patients receiving atenolol (two-sided 95% confidence interval: −10.3; 7.7). The proportions of patients titrated to a higher dose were 34.5% and 32.9% for olmesartan and atenolol, respectively. Mean pulse rates (± s.d.) at baseline and at 12 weeks were 74.6 (± 8.0) bpm and 73.1 (± 8.4) bpm in the olmesartan group, and 74.0 (± 8.3) and 67.0 (± 8.7) in the atenolol group, respectively. At 12 weeks, the results showed a clear superiority for olmesartan in reducing both DBP and SBP from baseline levels ( Figure 2 ). The adjusted mean changes from baseline in sitting DBP (± s.e.m.) were −9.9 (± 0.6) mm Hg and −6.8 (± 0.6) mm Hg, and adjusted mean changes in sitting SBP were −14.7 (± 1.1) mm Hg and −7.1 (± 1.1) mm Hg in the olmesartan and captopril groups, respectively. The 95% confidence intervals (DBP: −4.8; −1.5; SBP: −10.4; −4.7) did not encompass zero, indicating that these differences were significant. There was a significantly higher responder rate in the olmesartan than in the captopril group (53% vs 38%; respectively, P Ͻ 0.01), and a smaller number of olmesartan-treated patients needed the highest dose compared with captopril-treated patients (25.0% vs 54.9%, respectively). In a higher proportion of patients, the target BP was achieved with a lower dose of olmesartan than captopril, indicating superiority of olmesartan. Table 2 shows that these changes were already evident after 4 and 8 weeks.
Comparison with captopril in patients with mild-to-moderate hypertension

Comparison with felodipine in patients with mild-to-moderate hypertension
Patients were studied to compare the efficacy of olmesartan with that of felodipine. Mild-to-moderate hypertension was defined as a mean sitting DBP of 100-120 mm Hg (100-114 mm Hg for Czech centres) during a 3-week placebo run-in phase. In total, 187 patients (baseline mean DBP of 104.6 mm Hg) were randomized to receive olmesartan medoxomil 20 mg o.d., and a further 194 patients (baseline mean DBP of 105.0 mm Hg) received felodipine 5 mg o.d. The dose was doubled after 4 weeks for non-responders in each group. After 12 weeks of treatment the effects of olmesartan on DBP and SBP were not significantly different from those of felodipine. The results at 2, 4 and 8 weeks also showed no significant differences between olmesartan-and felodipine-treated patients in terms of change from baseline in DBP and SBP (Table 3 ). The responder rates at week 12 were 
Comparison with losartan in patients with mildto-moderate hypertension
In the study comparing olmesartan with losartan, mild-to-moderate hypertension was defined as a mean sitting DBP of 95-114 mm Hg during a 3-week placebo run-in period. A total of 160 patients (baseline mean DBP of 101.3 mm Hg) were randomised to receive olmesartan medoxomil 10 mg o.d., and another 156 patients (baseline mean DBP of 101.9 mm Hg) received losartan 50 mg o.d. The dose was increased at week 4 for non-responders in each group. The primary time point for efficacy was 12 weeks, after which the study was extended for a further 12 weeks. From weeks 12 to 24, concomitant HCTZ at dosages of 12.5 mg or 25 mg o.d. was prescribed where necessary. Figure 3 shows that after 12 weeks of treatment olmesartan had induced a significantly greater reduction in both DBP and SBP. The adjusted mean changes in sitting DBP (± s.e.m.) in the olmesartan and losartan groups were −10.6 (± 0.5) mm Hg and −8.5 (± 0.6) mm Hg, respectively (two-sided 95% confidence interval: −3.6; −0.5). The adjusted mean changes in sitting SBP (± s.e.m.) in the olmesartan and losartan groups were −14.9 (± 1.0) mm Hg and −11.6 (± 1.0) mm Hg (two-sided 95% confidence interval: −6.0; −0.6). The responder rates at week 12 were 63% vs 52% for the olmesartan and losartan groups, respectively. The percentage of patients on a higher dose by week 12 was lower in the olmesartan group than in the losartan group (41.8% vs 63.2%). Of special interest are the results at weeks 2 and 4, when all patients received the low dose of their respective drug, as shown in Table 4 . The results at weeks 16, 20 and 24 still showed some superiority for olmesartan, but the differences were no longer significant. It is noted that a lower percentage of olmesartan-treated patients needed HCTZ compared Figure 3 Change in blood pressure (BP) (adjusted mean ± s.e.m.) from baseline in patients with mild-to-moderate hypertension after 12 weeks of treatment with olmesartan compared with losartan. † Significant difference, 95% confidence interval −3.6; −0.6; * significant difference, 95% confidence interval −6.0; −0.6. 
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Tolerability
Adverse events occurred at similar frequencies on the active treatments in the comparative studies and some expected differences in profile were observed. For example, among felodipine-treated patients there was a higher rate of peripheral oedema (2.6%) than among olmesartan-treated patients (0%). Overall, the great majority of adverse events in each study were mild or moderate in severity. In general, all treatments were considered to be well tolerated over the study period.
Discussion
The comparative studies demonstrated that, in patients with moderate-to-severe hypertension, olmesartan medoxomil (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) 1, 7 Even at these lower doses, however, olmesartan maintained efficacy similar or superior to that of the comparators. In the studies comparing olmesartan with captopril and losartan, fewer patients were titrated to higher doses of olmesartan than in the case of either captopril or losartan. (The starting doses used for the comparators in these trials matched the current recommended starting doses, ie captopril 12.5 mg b.i.d. and losartan 50 mg o.d.) It could therefore be expected that adequate BP control may be achieved in a greater proportion of patients on the recommended starting dose of olmesartan than those on the recommended starting dose of either captopril or losartan. A recent trial has compared the dose of olmesartan 20 mg with the maintenance doses of three commonly prescribed A II receptor blockers. 10, 11 After 8 weeks of treatment, the reduction in mean cuff DBP (11.5 mm Hg) was significantly greater in patients treated with olmesartan than those treated with losartan (50 mg), valsartan (80 mg) or irbesartan (150 mg) (8.2, 7.9 and 9.9 mm Hg, respectively). The risk of cardiovascular events is reported to be decreased in patients with adequately controlled BP, 12 yet the majority of treated patients do not experience good BP control. 13 Novel drugs able to control BP rapidly without the need for lengthy dose titration regimens would therefore be a valuable addition to the currently available range of antihypertensive drugs.
